The World Health Organization (WHO), the agency of the United Nations responsible for overseeing matters related to global health, revealed that 2025 was marked by notable progress in ensuring populations around the world were supported to have good health. However, climate shocks, conflicts and funding cuts strained many health systems around the world and put a damper on the prospects for sustained improvements to health in the years to come.
Regarding disease control, the health body highlighted notable successes that were registered. For example, it pointed out a number of countries that hit historic milestones in the elimination of infectious diseases. Brazil stood out as the first-ever populous nation in the Americas to eliminate the transmission of HIV from mother to child. Maldives recorded a triple victory of eliminating hepatitis B, syphilis and the transmission of HIV from mother-to-child.
Successes were also recorded with regard to neglected tropical diseases. For example, sleeping sickness was eliminated from Kenya and Guinea. Trachoma was eliminated from Fiji, Egypt and Burundi. Niger made history by being the first nation in Africa to kick out river blindness.
Fatalities from tuberculosis have continued their downward trend, with a drop of approximately 45% occurring within the past 10 years. However, projections indicate the disease still led to the death of 1.2 million individuals in 2024 around the globe, showing that a lot more work still needs to be done.
The World Health Organization also commended the progress that was registered in nurturing cooperation across the globe on matters of health. A Pandemic Agreement, the first such agreement on a global scale, was adopted in 2025 and it sets a strong foundation upon which the world can respond to future pandemics quickly and more equitably. Progress was also registered on the front of non-communicable diseases. A political declaration was endorsed by global leaders recognizing the impact that these illnesses have on mental health.
As 2026 gets underway, the UN agency reaffirms its commitment to rebuild a safer, healthier future for everyone on the globe. This will be attained through sustained solidarity and science-backed solutions to address existing and emerging threats to health. It remains to be seen how the agency will deliver on its mandate despite funding pressures, disruptions caused by conflicts in different parts of the world and the increasing climate-linked shocks being experienced.
All stakeholders need to do everything they can to support the attainment of good health for each individual around the world. The efforts of companies like Soligenix Inc. (NASDAQ: SNGX) directed at developing therapeutics and vaccines indicated for infectious diseases and other biothreats could go a long way in supporting the overarching mission of WHO and other agencies to ensure everyone is healthy.
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
